Using Interleukin 2 After Chemo-Radiotherapy for Blood Cancer
Author Information
Author(s): D.J. Gottlieb, M.K. Brenner, H.E. Heslop, A.C.M. Bianchi, C. Bello-Fernandez, A.B. Mehta, A.C. Newland, A.R. Galazka, E.M. Scott, A.V. Hoffbrand, H.G. Prentice
Primary Institution: Royal Free Hospital
Hypothesis
Can interleukin 2 (IL2) help eliminate minimal residual disease in patients after intensive chemotherapy or bone marrow transplantation?
Conclusion
IL2 can be safely administered to patients after intensive chemotherapy, potentially increasing their disease-free survival.
Supporting Evidence
- IL2 infusions produced no significant adverse effects on marrow regeneration.
- Neutrophil counts increased from a mean of 1.1 pre-infusion to 2.5 during the infusion.
- Cells with activity against leukaemic progenitor cells appeared in peripheral blood within 48 hours of beginning treatment.
Takeaway
This study tested a medicine called IL2 to see if it could help people with blood cancer stay healthy after strong treatments. It showed that IL2 might help without making them too sick.
Methodology
Patients received IL2 after intensive chemotherapy or bone marrow transplantation, and their health was monitored for side effects and blood cell counts.
Limitations
The study involved a small number of patients and focused on short-term effects.
Participant Demographics
9 male and 4 female patients aged 18 to 67, with a median age of 36.
Statistical Information
P-Value
0.004
Statistical Significance
p=0.004
Want to read the original?
Access the complete publication on the publisher's website